Euglycemic Diabetic Ketoacidosis Following Treatment with Tirzepatide and SGLT-2 Inhibitors: A Case Report and Literature Review.

Intern MedMar 17, 2026 (epub)

Toshitaka Sawamura, Shigehiro Karashima, Ai Ohmori et al.

✦ AI-curated · Sources linked

Case in brief

A patient receiving tirzepatide and an SGLT-2 inhibitor developed euglycemic diabetic ketoacidosis while continuing both medications during a sick-day condition. The report highlights appetite loss as a relevant concern with tirzepatide and the potential for EDKA in the setting of SGLT-2 inhibitor use. After the sick-day condition resolved, both agents were reintroduced successfully, with no adverse effects reported.

What made this case unusual

EDKA occurred while the patient continued both tirzepatide and an SGLT-2 inhibitor during a sick-day condition; both medications were later reintroduced without reported adverse effects.

Diagnostic / clinical pearl

During sick-day conditions, consider EDKA in patients taking SGLT-2 inhibitors, particularly when appetite loss accompanies continued tirzepatide use.

Source

Published in Intern Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.